Litcius/Paper detail

Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials

Mei‐Jyh Chen, Po‐Yueh Chen, Yu‐Jen Fang, Ming‐Jong Bair, Chieh‐Chang Chen, Chien-Chuan Chen, Tsung‐Hua Yang, Ji‐Yuh Lee, Chien-Chun Yu, Chia‐Chi Kuo, Min‐Chin Chiu, Chu‐Kuang Chou, Chi-Yi Chen, Wen-Hao Hu, Min‐Horn Tsai, Yao‐Chun Hsu, Chia‐Tung Shun, Jiing–Chyuan Luo, Jaw‐Town Lin, Emad El‐Omar, Ming‐Shiang Wu, Jyh‐Ming Liou

2023˜The œLancet. Gastroenterology & hepatology36 citationsDOI

Topics & Concepts

MedicineHelicobacter pyloriClarithromycinInternal medicineLevofloxacinRandomized controlled trialClinical endpointGastroenterologyAntibioticsBiologyMicrobiologyHelicobacter pylori-related gastroenterology studiesGastric Cancer Management and OutcomesMicroscopic Colitis
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials | Litcius